Skip to content

shoulder tendinopathy

shoulder tendinopathy - sr

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00011054
Enrollment
80
Registered
2017-01-16
Start date
2016-02-10
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M25.51

Interventions

Group 1: shock wave therapy (ESWT) of the painful shoulder. 2000 impulses per session, 0.32mmJ/mm², 4Hz using Duolith SD 1 (Storz Medical) . Focusing the point of most tenderness. Total of 3 sessions

Sponsors

Klinik für Orthopädie und Unfallchirurgie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: •Symptomatic rotator cuff tendinopathy •At least a 3-month duration of symptoms •Must complete and failed to conservative treatment with: oPhysical therapy and ophysiotherapy oSystemic NSAID´s •NSAIDs treatment washout period of 1 weeks •No calcific tendinitis •Signed informed consent •VAS pain score > 4 •Age greater than 18 years

Exclusion criteria

Exclusion criteria: •Glenohumeral or acromioclavicular joint arthrosis •Previous surgery of the painful shoulder •Bursitis/ infection/ tumor of the shoulder •Shoulder Instability/ clinically significant complete rotator cuff lesion of the shoulder •Pathological neurological findings •VAS Pain score < 5 •Significant coagulation disturbance •Previous unsuccessful ESWT

Design outcomes

Primary

MeasureTime frame
shoulder pain measured by visual analogue scale (VAS) 6, 12 and 24 month after last intervention

Secondary

MeasureTime frame
funcunal outcome of the painful shoulder measured by Constant Murley Score (CMS) 6, 12 and 24 month after last intervention

Countries

Germany

Contacts

Public ContactLudger Gerdesmeyer

Klinik für Orthopädie und Unfallchirurgie

Ludger.Gerdesmeyer@uksh.de04315975505

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026